Industry shows increased appetite for macrophage biology

Macrophage-focused immuno-oncology programmes were in the doldrums just a year ago, but are now back on the move in the wake of Gilead Sciences’ US$4.9 billion acquisition of Forty Seven. Macrophage-focused immuno-oncology programmes were in the doldrums just a year ago, but are now back on the move in the wake of Gilead Sciences’ US$4.9 billion acquisition of Forty Seven.